Navigation Links
FDA Approves Multaq(R) for Patients with Atrial Fibrillation or Atrial Flutter
Date:7/2/2009

trial fibrillation is a complex disease that increases the risk of stroke up to five-fold, worsens the prognosis of patients with cardiovascular risk factors, and doubles the risk of mortality. Atrial flutter, another type of arrhythmia generating in the atrium, occurs less frequently, and may evolve into atrial fibrillation.

About sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Forward Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include product development, product potential projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future events, operations, products and services, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans" and similar expressions. Although sanofi-aventis' management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among
'/>"/>

SOURCE sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7

Related medicine news :

1. FDA Approves Lamictal(R)XR(TM); An Extended-Release Once-Daily, New Generation Treatment for Epilepsy
2. FDA Approves Reclast(R) to Prevent Osteoporosis in Postmenopausal Women With Convenient Less Frequent Dosing
3. FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia
4. ClearWay Minnesota(SM) Board Approves Four Regional Grants
5. Department of Defense Approves ISSA as Fitness Education Provider to Military Spouses
6. FDA Approves ACTOplus met(R) XR (pioglitazone HCl and metformin HCl extended-release) Tablets for the Treatment of Type 2 Diabetes
7. Treating Untreatable Brain Tumors: FDA Approves New Laser Surgery
8. FDA Approves Lamictal(R) ODT(TM) Orally Disintegrating Tablets
9. Video: FDA approves Exforge HCT(R) - the Only High Blood Pressure Treatment to Combine Three Medications in a Single Pill
10. Kaiser Permanente Approves $13 Million in Community Benefit Grants in First Quarter of 2009
11. FDA Approves Plan B Pill for 17-Year-Olds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... Digital Pen and Paper technology and the provider of the ... that it is ranked among the Fastest Growing Technology Companies ... , ... (PRWEB) December 16, 2009 -- ... capture, digitalization and management of handwritten data. Kayentis targets the ...
(Date:12/16/2009)... Massachusetts companies through annual marketing campaign , ... ... unveiled the 2010 Genetown™ Hotbed Campaign as its ... ,Genetown is sponsored by MassBio and showcases 37 ... campaign places each entity’s brand on an electronic and ...
(Date:12/16/2009)... About 8 percent of children are uninsured, government report ... the first six months of this year, 45.4 million ... the population -- had no health insurance, according to ... In addition, 58.4 million (19.4 percent) people of all ... the year prior to the interview, and 31.9 million ...
(Date:12/16/2009)... Shoppers like knowing if their salad is from ... have found it burdensome to implement the recent ... to provide the information at point of sale. ... for easily making grocery and produce signs debuts ... retailers of unprocessed fruits, vegetables and other agricultural ...
(Date:12/16/2009)... travel facilitator Companion Global Healthcare Inc. has accepted ... network of international hospitals that treat American patients ... U.S. facilities. ,, The announcement means Companion Global ... pricing for its individual clients and employer group ... Pablo Bayamon or HIMA San Pablo Caguas. ,, ...
Breaking Medicine News(10 mins):Health News:With a Revenue Growth of Over 500% During the Last 5 Years, Kayentis is Ranked on the Deloitte Technology Fast 500 -- EMEA 2009 2Health News:Thriving Bioscience Region Leaves Its Mark 2Health News:Over 45 Million Americans Now Lack Health Insurance 2Health News:New Website Helps Grocers Comply With COOL Laws 2Health News:Hospitals in Puerto Rico Join Companion Global Healthcare's Network 2
... pregnancy are more likely to bear an underweight child, ... others because of genetic susceptibility.// The finding could help ... though the researchers said they were not recommending at ... the genes involved. ,"Our data demonstrate that ...
... that immunisation can protect against cot deaths in babies.Sudden ... death in children over one month old,//even though advice ... the numbers of deaths. ,Scientists from Bristol ... from between 1984 and 1994, checking to see if ...
... Millions of Americans have been drinking tap water contaminated ... to disinfect drinking water.// When it is added to ... farms or lawns, however, it can form compounds such ... study released by the Environmental Working Group and Public ...
... developed by a research team from Southampton University,which works by ... the immune cells in the blood.//The lymphoma cells are not ... multiply diversely. ... a sample of tumour cells from a patient, and ...
... painful to excrete, cost billions of dollars each year ... can sometimes be prevented by drinking plenty of water, ... reduce the excretion of calcium in urine may be ... bloating and other uncomfortable side effects. ,Men who ...
... America has developed a micro capsule coated with silicon, ... injection.This microchip works by absorbing nutrients from the ... to inject insulin more than onece a day to ... being developed by Tejal Desai of the University of ...
Other Medicine News:
(Date:12/16/2009)... 16 Ethicon, Inc., a Johnson & ... a worldwide leader in surgical care, and Acclarent, ... to designing, developing and commercializing devices that address ... today announced a definitive merger agreement whereby Ethicon ... approximately $785 million net of estimated cash on ...
(Date:12/16/2009)... -- Hospira, Inc. (NYSE: HSP ), a ... announced that it will host a conference call to ... for 2010 on Thursday, Feb. 4, 2010, at 8 ... fourth-quarter and full-year 2009 results earlier that morning, before ... ,, A live webcast of the conference call will ...
(Date:12/16/2009)... 16 International, well-known,scientific experts ... GFT505 (80 mg/day),data presented as "extremely ... scientists and clinicians critically reviewed these ... of generic lipid-modifying,treatments, fenofibrate and bezafibrate, ... observed in patients with metabolic syndrome,and ...
Breaking Medicine Technology:Ethicon Announces Definitive Agreement to Acquire Acclarent 2Ethicon Announces Definitive Agreement to Acquire Acclarent 3Ethicon Announces Definitive Agreement to Acquire Acclarent 4International, Well-Known Scientific Experts Say That New GFT505 Data Unlikely to Have the Potential to Affect the Established Role of Generic Fenofibrate and Bezafibrate in Managing Atherogenic Dyslipidemia 2International, Well-Known Scientific Experts Say That New GFT505 Data Unlikely to Have the Potential to Affect the Established Role of Generic Fenofibrate and Bezafibrate in Managing Atherogenic Dyslipidemia 3U S Patent Infringement Lawsuit Filed by Aperio Technologies Inc 49838 1U S Patent Infringement Lawsuit Filed by Aperio Technologies Inc 49838 2National Medical Association Applauds President Obamas and Senator Baucuss Efforts to Work With PhRMA to Bring Down Health Care Costs and Advance Mean 49834 1Putney Inc Enters the 24175M Annual Veterinary NSAID Market 49830 1Putney Inc Enters the 24175M Annual Veterinary NSAID Market 49830 2
... 18 LigoCyte Pharmaceuticals,Inc., today announced a ... develop therapies targeting CD103 for the treatment ... autoimmune indications. CD103 is the unique alphaE-beta7 ... homing and retention of lymphocytes,that mediate inflammatory ...
... live at http://www.wilsoncenter.org/globalhealth , WASHINGTON, Sept. 17 ... a reauthorization of the President,s,Emergency Plan for AIDS Relief ... fiscal year 2008. The plan calls for an increase ... to $30 billion over the next five,years., On ...
Other Medicine Technology:Director's Forum: PEPFAR and the Global AIDS Response 2
... ToRCH Plus IgM Controls identify ... in your ToRCH IgM immunoassay ... test results. Liquichek ToRCH Plus ... complement to Liquichek ToRCH Plus ...
... Liquichek ToRCH Plus Control is ... to monitor the performance of ... instruments and assays. A weak ... allow you to monitor the ...
Liquichek Unassayed Chemistry Control (Human) is a comprehensive, stable, liquid product designed to monitor general and special chemistry tests....
... Lyphochek Unassayed Chemistry Control (Human) provides ... stability for enzymes and CO2. It ... compatible with most major instruments and ... 10 mL fill sizes (10 mL ...
Medicine Products: